Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens

Magdalini Moutaftsi, David C. Tscharke, Kerrie Vaughan, David M. Koelle, Lawrence Stern, Mauricio Calvo-Calle, Francis Ennis, Masanori Terajima, Gerd Sutter, Shane Crotty, Ingo Drexler, Genoveffa Franchini, Jon W. Yewdell, Steven R. Head, Janice Blum, Bjoern Peters, Alex Sette

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Vaccinia virus (VACV) was used as the vaccine strain to eradicate smallpox. VACV is still administered to healthcare workers or researchers who are at risk of contracting the virus, and to military personnel. Thus, VACV represents a weapon against outbreaks, both natural (e.g., monkeypox) or man-made (bioterror). This virus is also used as a vector for experimental vaccine development (cancer/infectious disease). As a prototypic poxvirus, VACV is a model system for studying host-pathogen interactions. Until recently, little was known about the targets of host immune responses, which was likely owing to VACVs large genome (>200 open reading frames). However, the last few years have witnessed an explosion of data, and VACV has quickly become a useful model to study adaptive immune responses. This review summarizes and highlights key findings based on identification of VACV antigens targeted by the immune system (CD4, CD8 and antibodies) and the complex interplay between responses.

Original languageEnglish
Pages (from-to)221-239
Number of pages19
JournalFuture Microbiology
Volume5
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Vaccinia virus
Antibody Formation
Monkeypox
Viruses
Poxviridae
Host-Pathogen Interactions
Cancer Vaccines
Smallpox
Weapons
Explosions
Military Personnel
Adaptive Immunity
Open Reading Frames
Disease Outbreaks
Communicable Diseases
Immune System
Vaccines
Research Personnel
Genome
Delivery of Health Care

Keywords

  • Adaptiv immuntly
  • Epitopes
  • Immunodominant
  • Protection
  • Vaccinia virus

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

Moutaftsi, M., Tscharke, D. C., Vaughan, K., Koelle, D. M., Stern, L., Calvo-Calle, M., ... Sette, A. (2010). Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiology, 5(2), 221-239. https://doi.org/10.2217/fmb.09.110

Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. / Moutaftsi, Magdalini; Tscharke, David C.; Vaughan, Kerrie; Koelle, David M.; Stern, Lawrence; Calvo-Calle, Mauricio; Ennis, Francis; Terajima, Masanori; Sutter, Gerd; Crotty, Shane; Drexler, Ingo; Franchini, Genoveffa; Yewdell, Jon W.; Head, Steven R.; Blum, Janice; Peters, Bjoern; Sette, Alex.

In: Future Microbiology, Vol. 5, No. 2, 02.2010, p. 221-239.

Research output: Contribution to journalArticle

Moutaftsi, M, Tscharke, DC, Vaughan, K, Koelle, DM, Stern, L, Calvo-Calle, M, Ennis, F, Terajima, M, Sutter, G, Crotty, S, Drexler, I, Franchini, G, Yewdell, JW, Head, SR, Blum, J, Peters, B & Sette, A 2010, 'Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens', Future Microbiology, vol. 5, no. 2, pp. 221-239. https://doi.org/10.2217/fmb.09.110
Moutaftsi M, Tscharke DC, Vaughan K, Koelle DM, Stern L, Calvo-Calle M et al. Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiology. 2010 Feb;5(2):221-239. https://doi.org/10.2217/fmb.09.110
Moutaftsi, Magdalini ; Tscharke, David C. ; Vaughan, Kerrie ; Koelle, David M. ; Stern, Lawrence ; Calvo-Calle, Mauricio ; Ennis, Francis ; Terajima, Masanori ; Sutter, Gerd ; Crotty, Shane ; Drexler, Ingo ; Franchini, Genoveffa ; Yewdell, Jon W. ; Head, Steven R. ; Blum, Janice ; Peters, Bjoern ; Sette, Alex. / Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. In: Future Microbiology. 2010 ; Vol. 5, No. 2. pp. 221-239.
@article{f06f620980a24bbcafb608d4cb20e04d,
title = "Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens",
abstract = "Vaccinia virus (VACV) was used as the vaccine strain to eradicate smallpox. VACV is still administered to healthcare workers or researchers who are at risk of contracting the virus, and to military personnel. Thus, VACV represents a weapon against outbreaks, both natural (e.g., monkeypox) or man-made (bioterror). This virus is also used as a vector for experimental vaccine development (cancer/infectious disease). As a prototypic poxvirus, VACV is a model system for studying host-pathogen interactions. Until recently, little was known about the targets of host immune responses, which was likely owing to VACVs large genome (>200 open reading frames). However, the last few years have witnessed an explosion of data, and VACV has quickly become a useful model to study adaptive immune responses. This review summarizes and highlights key findings based on identification of VACV antigens targeted by the immune system (CD4, CD8 and antibodies) and the complex interplay between responses.",
keywords = "Adaptiv immuntly, Epitopes, Immunodominant, Protection, Vaccinia virus",
author = "Magdalini Moutaftsi and Tscharke, {David C.} and Kerrie Vaughan and Koelle, {David M.} and Lawrence Stern and Mauricio Calvo-Calle and Francis Ennis and Masanori Terajima and Gerd Sutter and Shane Crotty and Ingo Drexler and Genoveffa Franchini and Yewdell, {Jon W.} and Head, {Steven R.} and Janice Blum and Bjoern Peters and Alex Sette",
year = "2010",
month = "2",
doi = "10.2217/fmb.09.110",
language = "English",
volume = "5",
pages = "221--239",
journal = "Future Microbiology",
issn = "1746-0913",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens

AU - Moutaftsi, Magdalini

AU - Tscharke, David C.

AU - Vaughan, Kerrie

AU - Koelle, David M.

AU - Stern, Lawrence

AU - Calvo-Calle, Mauricio

AU - Ennis, Francis

AU - Terajima, Masanori

AU - Sutter, Gerd

AU - Crotty, Shane

AU - Drexler, Ingo

AU - Franchini, Genoveffa

AU - Yewdell, Jon W.

AU - Head, Steven R.

AU - Blum, Janice

AU - Peters, Bjoern

AU - Sette, Alex

PY - 2010/2

Y1 - 2010/2

N2 - Vaccinia virus (VACV) was used as the vaccine strain to eradicate smallpox. VACV is still administered to healthcare workers or researchers who are at risk of contracting the virus, and to military personnel. Thus, VACV represents a weapon against outbreaks, both natural (e.g., monkeypox) or man-made (bioterror). This virus is also used as a vector for experimental vaccine development (cancer/infectious disease). As a prototypic poxvirus, VACV is a model system for studying host-pathogen interactions. Until recently, little was known about the targets of host immune responses, which was likely owing to VACVs large genome (>200 open reading frames). However, the last few years have witnessed an explosion of data, and VACV has quickly become a useful model to study adaptive immune responses. This review summarizes and highlights key findings based on identification of VACV antigens targeted by the immune system (CD4, CD8 and antibodies) and the complex interplay between responses.

AB - Vaccinia virus (VACV) was used as the vaccine strain to eradicate smallpox. VACV is still administered to healthcare workers or researchers who are at risk of contracting the virus, and to military personnel. Thus, VACV represents a weapon against outbreaks, both natural (e.g., monkeypox) or man-made (bioterror). This virus is also used as a vector for experimental vaccine development (cancer/infectious disease). As a prototypic poxvirus, VACV is a model system for studying host-pathogen interactions. Until recently, little was known about the targets of host immune responses, which was likely owing to VACVs large genome (>200 open reading frames). However, the last few years have witnessed an explosion of data, and VACV has quickly become a useful model to study adaptive immune responses. This review summarizes and highlights key findings based on identification of VACV antigens targeted by the immune system (CD4, CD8 and antibodies) and the complex interplay between responses.

KW - Adaptiv immuntly

KW - Epitopes

KW - Immunodominant

KW - Protection

KW - Vaccinia virus

UR - http://www.scopus.com/inward/record.url?scp=77950865479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950865479&partnerID=8YFLogxK

U2 - 10.2217/fmb.09.110

DO - 10.2217/fmb.09.110

M3 - Article

VL - 5

SP - 221

EP - 239

JO - Future Microbiology

JF - Future Microbiology

SN - 1746-0913

IS - 2

ER -